Literature DB >> 20852034

Cannabinoid CB₁ receptor is downregulated in clear cell renal cell carcinoma.

Gorka Larrinaga1, Begoña Sanz, Itxaro Pérez, Lorena Blanco, María L Cándenas, Francisco M Pinto, Javier Gil, José I López.   

Abstract

Several studies in cell cultures and in animal models have demonstrated that cannabinoids have important antitumoral properties. Because many of these effects are mediated through cannabinoid (CB) receptors CB₁ and CB₂, the study of their expression in human neoplasms has become of great interest in recent years. Fresh and formalin-fixed tissue samples of 20 consecutive clear cell renal cell carcinomas (CCRCCs) were collected prospectively and analyzed for the expression of both CB receptors by using RT-PCR, Western blot (WB), and immunohistochemical techniques. RT-PCR assays demonstrated the expression of mRNA encoding the CB₁ in tumor tissue and in adjacent non-neoplastic kidney. Conversely, WB and IHC revealed a marked downregulation of CB₁ protein in tumor tissue; CB₂ was not expressed. The obtained data suggest a possible implication of the endocannabinoid system in renal carcinogenesis. A posttranscriptional downregulation of CB₁ and the absence of expression of CB₂ characterize CCRCC.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20852034      PMCID: PMC2989249          DOI: 10.1369/jhc.2010.957126

Source DB:  PubMed          Journal:  J Histochem Cytochem        ISSN: 0022-1554            Impact factor:   2.479


  29 in total

1.  Primer3 on the WWW for general users and for biologist programmers.

Authors:  S Rozen; H Skaletsky
Journal:  Methods Mol Biol       Date:  2000

2.  Characterization of CB1 cannabinoid receptor immunoreactivity in postmortem human brain homogenates.

Authors:  M López De Jesús; J Sallés; J J Meana; L F Callado
Journal:  Neuroscience       Date:  2006-03-23       Impact factor: 3.590

3.  Delta9-tetrahydrocannabinol inhibits cell cycle progression in human breast cancer cells through Cdc2 regulation.

Authors:  María M Caffarel; David Sarrió; José Palacios; Manuel Guzmán; Cristina Sánchez
Journal:  Cancer Res       Date:  2006-07-01       Impact factor: 12.701

4.  Single-step method of RNA isolation by acid guanidinium thiocyanate-phenol-chloroform extraction.

Authors:  P Chomczynski; N Sacchi
Journal:  Anal Biochem       Date:  1987-04       Impact factor: 3.365

Review 5.  Role of molecular markers in the diagnosis and therapy of renal cell carcinoma.

Authors:  John S Lam; John T Leppert; Robert A Figlin; Arie S Belldegrun
Journal:  Urology       Date:  2005-11       Impact factor: 2.649

6.  Expression of cannabinoid receptors in human kidney.

Authors:  Gorka Larrinaga; Adolfo Varona; Itxaro Pérez; Begoña Sanz; Aitziber Ugalde; M Luz Cándenas; Francisco M Pinto; Javier Gil; José I López
Journal:  Histol Histopathol       Date:  2010-09       Impact factor: 2.303

Review 7.  2004 WHO classification of the renal tumors of the adults.

Authors:  Antonio Lopez-Beltran; Marina Scarpelli; Rodolfo Montironi; Ziya Kirkali
Journal:  Eur Urol       Date:  2006-01-17       Impact factor: 20.096

8.  Cannabinoid receptor as a novel target for the treatment of prostate cancer.

Authors:  Sami Sarfaraz; Farrukh Afaq; Vaqar M Adhami; Hasan Mukhtar
Journal:  Cancer Res       Date:  2005-03-01       Impact factor: 12.701

9.  Cannabinoids induce cancer cell proliferation via tumor necrosis factor alpha-converting enzyme (TACE/ADAM17)-mediated transactivation of the epidermal growth factor receptor.

Authors:  Stefan Hart; Oliver M Fischer; Axel Ullrich
Journal:  Cancer Res       Date:  2004-03-15       Impact factor: 12.701

10.  Prognostic significance of morphologic parameters in renal cell carcinoma.

Authors:  S A Fuhrman; L C Lasky; C Limas
Journal:  Am J Surg Pathol       Date:  1982-10       Impact factor: 6.394

View more
  10 in total

1.  Coronary Vasospasm Associated With Synthetic Marijuana Resulting in Transient Electrocardiogram Changes and Troponin Elevation.

Authors:  Syed S Fatmi; Andrew Outlaw
Journal:  Cureus       Date:  2022-05-17

Review 2.  Systematic review of the potential role of cannabinoids as antiproliferative agents for urological cancers.

Authors:  Shreyas Gandhi; Gaurav Vasisth; Anil Kapoor
Journal:  Can Urol Assoc J       Date:  2017-04-11       Impact factor: 1.862

3.  Overexpression of cannabinoid receptor 1 promotes renal cell carcinoma progression.

Authors:  Jianfeng Wang; Yunze Xu; Yun Zou; Liangsong Zhu; Baijun Dong; Jiwei Huang; Yonghui Chen; Wei Xue; Yiran Huang; Wen Kong; Jin Zhang
Journal:  Tumour Biol       Date:  2016-10-18

4.  Anandamide inhibits transport-related oxygen consumption in the loop of Henle by activating CB1 receptors.

Authors:  Guillermo B Silva; Douglas K Atchison; Luis I Juncos; Néstor H García
Journal:  Am J Physiol Renal Physiol       Date:  2012-12-05

Review 5.  The dynamic nature of type 1 cannabinoid receptor (CB(1) ) gene transcription.

Authors:  R B Laprairie; M E M Kelly; E M Denovan-Wright
Journal:  Br J Pharmacol       Date:  2012-12       Impact factor: 8.739

6.  Cannabinoid receptor 2 as a novel target for promotion of renal cell carcinoma prognosis and progression.

Authors:  Jianfeng Wang; Yunze Xu; Liangsong Zhu; Yun Zou; Wen Kong; Baijun Dong; Jiwei Huang; Yonghui Chen; Wei Xue; Yiran Huang; Jin Zhang
Journal:  J Cancer Res Clin Oncol       Date:  2017-10-09       Impact factor: 4.553

7.  Immunohistochemical assessment of cannabinoid type-1 receptor (CB1R) and its correlation with clinicopathological parameters in glioma.

Authors:  Nader Choucair; Zahraa Saker; Hassane Kheir Eddine; Hisham F Bahmad; Youssef Fares; Mariana Zaarour; Hayat Harati; Sanaa Nabha
Journal:  Pathologica       Date:  2022-04

Review 8.  Endocannabinoid system as a regulator of tumor cell malignancy - biological pathways and clinical significance.

Authors:  Maria Pyszniak; Jacek Tabarkiewicz; Jarogniew J Łuszczki
Journal:  Onco Targets Ther       Date:  2016-07-18       Impact factor: 4.147

9.  Involvement of the CB2 cannabinoid receptor in cell growth inhibition and G0/G1 cell cycle arrest via the cannabinoid agonist WIN 55,212-2 in renal cell carcinoma.

Authors:  Mohammed I Khan; Anna A Sobocińska; Klaudia K Brodaczewska; Katarzyna Zielniok; Malgorzata Gajewska; Claudine Kieda; Anna M Czarnecka; Cezary Szczylik
Journal:  BMC Cancer       Date:  2018-05-23       Impact factor: 4.430

Review 10.  The Therapeutic Aspects of the Endocannabinoid System (ECS) for Cancer and their Development: From Nature to Laboratory.

Authors:  Mohammed I Khan; Anna A Sobocińska; Anna M Czarnecka; Magdalena Król; Bruno Botta; Cezary Szczylik
Journal:  Curr Pharm Des       Date:  2016       Impact factor: 3.116

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.